RIGL
Rigel Pharmaceuticals

12,439
Mkt Cap
$628.4M
Volume
426,415.00
52W High
$52.24
52W Low
$15.50
PE Ratio
5.61
RIGL Fundamentals
Price
$33.02
Prev Close
$34.62
Open
$34.12
50D MA
$38.18
Beta
1.35
Avg. Volume
290,779.77
EPS (Annual)
$0.9886
P/B
5.34
Rev/Employee
$1.09M
$280.14
Loading...
Loading...
News
all
press releases
Rigel Pharmaceuticals Q4 Earnings Call Highlights
Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5h ago
News Placeholder
Earnings Summary: Rigel Pharmaceuticals Q4
read more...
Benzinga·6h ago
News Placeholder
Rigel Pharmaceuticals (NASDAQ:RIGL) Announces Earnings Results
Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported $13.54 earnings per share (EPS) for the quarter, beating...
MarketBeat·6h ago
News Placeholder
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.
Zacks·12h ago
News Placeholder
A Preview Of Rigel Pharmaceuticals's Earnings
read more...
Benzinga·1d ago
News Placeholder
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options
Investors need to pay close attention to RIGL stock based on the movements in the options market lately.
Zacks·5d ago
News Placeholder
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +86.00% and +30.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Rigel Pharmaceuticals (NASDAQ:RIGL) Director Walter Moos Sells 4,000 Shares
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) Director Walter Moos sold 4,000 shares of Rigel Pharmaceuticals stock in a transaction on Friday, February 20th. The stock was sold at an...
MarketBeat·7d ago
<
1
2
...
>

Latest RIGL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.